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ABSTRACT
The oncogenic role of ectopic expression of Na+/H+ exchanger regulatory factor 
1 (NHERF1) was recently suggested in colorectal cancer, where it was implicated 
in playing a role in the tumor hypoxia microenvironment. Here we showed that a 
high level expression of NHERF1 was found in colorectal cancer tissues and that 
the expression of NHERF1 was positively correlated with VEGFR2 expression. The 
prognostic value of VEGFR2 expression in colorectal cancer relied on the expression 
of NHERF1. The up-regulation of NHERF1 induced by the exposure to hypoxia in colon 
cancer cells depended on the activation of VEGFR2 signaling. NHERF1 in turn inhibited 
the activation of VEGFR2 signaling which could be regulated by the interaction 
between NHERF1 and VEGFR2, resulting in the reduction of migration and invasion 
of colon cancer cells. These results suggest a dynamic interplay between NHERF1 
and VEGFR2 signaling in colorectal cancer, which could explain the contribution of 
NHERF1 to the regulation of tumor cell responses to the hypoxia microenvironment.
INTRODUCTION
Despite very important therapeutic advances during 
the last decade, colorectal cancer (CRC) is the third most 
commonly diagnosed cancer in the world [1]. In 2016, 
new cases and deaths from CRC were estimated 134,490 
and 49,190 in the United States, respectively [2]. Surgical 
resection of localized tumors improves patients’ survival 
[3], but over half of them will develop a recurrence [4]. 
There is still a real need for therapies that would reduce the 
risk of recurrence after surgery and chemotherapy treatment 
and prolong patient survival with metastatic disease. 
In solid malignancies, fast proliferation can outgrow 
the supply of nutrients and oxygen provided by the 
malformed tumor vasculature [5]. Hypoxia is common 
in human cancers and grants stabilization of hypoxia-
inducible factor 1α (HIF1α) [5, 6]. This transcription 
factor ensures cell survival through adaptive changes 
in cell metabolism [5]. Among several hypoxia related 
genes, the vascular endothelial growth factors (VEGFs) 
mediate their effects on proliferation and survival mostly 
through the VEGF receptor 1 (VEGFR1) and 2 (VEGFR2) 
within endothelial cells [7, 8]. Nevertheless, it has been 
demonstrated that VEGFR1 and VEGFR2 expression 
in CRC cells correlated significantly with high risk of 
metastasis and relapse [9, 10]. 
VEGFs and their receptors are targets for 
cancer drug therapy [11]. Blockade of the VEGF/VEGFR 
pathway has shown efficacy and led to improvements in 
survival in CRC [12, 13]. However, patient responses 
to anti-VEGF/VEGFR therapies are variable within 
and across indications. Most of the reported outcomes 
are averages but in reality these vary quite extensively 
from complete response to no response [14, 15]. Many 
patients progress after initial disease stabilization due 
to acquired resistance to anti-VEGF/VEGFR drugs 
[16, 17]. Thus, it is very important to elucidate the 
regulation of VEGF/VEGFR2 pathway in vivo and it is 
crucial to find predictive biomarkers to identify patients 
that may benefit from anti-VEGF/VEGFR therapies. 
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Na+/H+ exchanger regulatory factor 1 (NHERF1), 
also named ezrin radixin-moesin (ERM) binding 
phosphoprotein 50 (EBP50), is a scaffolding protein, 
contains two N-terminal tandem domains PDZ1 and PDZ2 
and a C-terminal ERM domain [18]. NHERF1 can bind 
more than 30 proteins through PDZ domains [19], such as 
platelet-derived growth factor receptor (PDGFR) [20,21], 
epidermal growth factor receptor (EGFR) [22], β-catenin 
[23]. Recently, it has been reported that NHERF1 is 
involved in cancer progression, including breast cancer 
[24], hepatocellular carcinoma [23] and glioblastoma [25]. 
Other studies have showed that NHERF1 is considered a 
new player in colorectal cancer progression [26]. It has 
been reported that nuclear NHERF1 expression probably 
contributes to the malignant phenotype during the early 
stages of carcinogenesis [27, 28]. Also, cytoplasmic 
NHERF1 was higher in primary cancer than in adjacent 
normal mucosa, and tumors overexpressing NHERF1 
were associated with nodal and distant metastases, poor 
grade and lymphovascular invasion (LVI) [29]. It was 
also reported that expression of NHERF1 was strongly 
correlated with expression of HIF1ɑ and VEGFRs both 
in breast cancer and lymphatic metastastic colorectal 
cancer [30, 31], indicating that NHERF1 expression 
might be involved in metastatic progression by regulating 
the cell adaptive changes to the tumor microenvironment. 
However, the mechanism of NHERF1 up-regulation in 
cancers and the contribution of NHERF1 to the regulation 
in the metastatic progression were still unclear.
The experiments from this study revealed that 
there could be negative feedback in colon cancer cells 
where NHERF1 up-regulation was induced by hypoxia, 
depending on the activation of VEGFR2 signaling 
pathway, in turn reducing the phosphorylation promoted 
activation of VEGFR2 signaling, resulting in the 
inhibition of migration and invasion of colon cancer cells. 
These results suggest that NHERF1 could regulate the 
progression of CRC through the interplay with VEGFR2 
signaling pathway.
RESULTS
NHERF1 expression was associated with clinical 
status of colorectal cancer
NHERF1 protein expression was readily detected 
in normal and cancerous epithelial cells of colorectal 
tissues, but not in surrounding stromal cells (Figure 1A). 
NHERF1 transcripts were quantified in colorectal tissues 
including 64 colorectal cancer tissues and 50 adjacent 
normal tissues. NHERF1 transcripts demonstrated a 
higher level in tumors (p = 0.0083, Tumor vs Normal) 
(Table 1). An elevated level of NHERF1 expression 
was detected in samples from patients with recurrence 
(p = 0.014, recurrence vs disease free). NHERF1 transcript 
levels were also increased in samples from patients with 
metastasis compared with those from disease free patients, 
though there was no significant difference (p = 0.079) 
(Table 1). However, no relationship was observed in the 
colorectal cancer tissues between NHERF1 expression and 
other clinic variables including Dukes and TNM stages 
(Table 1). 
Prognostic value of VEGFR2 expression in 
colorectal cancer relied on the expression of 
NHERF1
In previous work from our team, a high VEGFR2 
level was found in colorectal cancer tissues compared to 
normal background tissues and was associated with disease 
progression [32]. In the present study, NHERF1 transcripts 
were quantified in the same tissue bank. A high level 
expression of NHERF1 was found in the colorectal cancer 
tissues and it was shown that NHERF1 expression was 
positively correlated with VEGFR2 expression (Table 2).
The colorectal cancer tissues were separated to 
two subgroups, NHERF1 low level group and NHERF1 
high level group, by the median value (2.0 copies) of 
NHERF1 transcripts quantified in colorectal tissues. The 
overall survival rates were analyzed in the two subgroups 
respectively. The mean OS was 99.3 [(58.4–140.2, 95% 
confidence interval (CI)] months in patients with high 
VEGFR2 expression levels (cut-off by median value (50 
copies) of VEGFR2 transcripts) and 140.4 (106.6–174.1, 
95% CI) months in patients with low VEGFR2 expression 
levels in the NHERF1 low level group (p = 0.02) (Figure 
1B). However no significant differences were observed 
in the OS curve analyse (p = 0.64) between patients with 
high and low VEGFR2 expression in the NHERF1 high 
level group (Figure 1C). 
Exposure to hypoxia increased NHERF1 
expression depending on the activation of 
VEGFR2 signaling pathway
We investigated the possible interaction between the 
hypoxia microenvironment and NHERF1 by subjecting 
colon cancer cells RKO to hypoxia. Western blot analysis 
revealed that exposure to hypoxia (1% O2) (Figure 2A) 
increased NHERF1 and VEGFR2 expression in RKO 
cells by the strong correlation with HIF-1α. In contrast, 
VEGFR2 special inhibitor ZM-323881 removed the up-
regulation of NHERF1 and VEGFR2 induced by hypoxia 
(Figure 2B). 
Effects of NHERF1 expression on the migration 
and invasion of RKO cells
The expression level of NHERF1 was considerably 
increased in Flag-NHERF1 plasmid transfected cells, 
compared with vector control cells (Figure 3A). Cells 
transfected with the anti-NHERF1 siRNAs exhibited a 
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markedly reduced level of NHERF1 expression compared 
with the scramble control (Figure 3B). Compared with 
control cells, cell migration was inhibited by up to 75% 
in cells overexpressing NHERF1 at 24 h (Figure 3C). 
This was consistent with the observations in NHERF1 
knockdown RKO cells, in which cells migration was 
increased up to 120% and 135% respectively (Figure 3D). 
Cell invasion was also reduced significantly in the NHERF1 
overexpression cells (Figure 3E); Knockdown of NHERF1 
expression resulted in a remarkable increase in invasive 
ability of RKO cells (Figure 3F). The inhibitory effect of 
NHERF1 on cell migration was also observed in colon 
cancer cells HRT-18 (Supplementary Figure S1A, S1B).
NHERF1 interacted with VEGFR2 in cells
It was recently reported that VEGF165 bound to 
VEGFR2 and NP1 results in the formation of a complex, 
which is dependent on the bridge of Synectin, a PDZ 
domain-containing protein [33, 34]. As a PDZ protein, 
it seemed a reasonable possibility that NHERF1 might 
form a protein complex with VEGFR2 in cells. To test 
this hypothesis, we employed a fusion protein pull-
down assay. As shown in Figure 4A, GST-NHERF1 
was found to robustly pull down VEGFR2. VEGFR-2 
immunoprecipitation from RKO cells followed by Western 
blot analysis revealed the formation of VEGFR2-NHERF1 
complex in cells (Figure 4B). Immunofluorescence was 
used to examine the subcellular localization of NHERF1 
and VEGFR2 in colorectal tissues. Representative images 
are shown in Figure 4C. VEGFR2 appeared to locate both 
in cytoplasm and membrane and being co-localized with 
NHERF1 (Figure 4C). 
NHERF1 inhibited VEGF165-induced VEGFR2, 
AKT and PLCγ activation 
Since NHERF1 can interact with VEGFR2 in cells, 
it was reasonable to assume that NHERF1 could also 
affect VEGFR2 signaling. To test this hypothesis, we 
detected VEGF165-induced phosphorylation activation of 
VEGFR2, AKT and PLCγ in RKO cells. VEGFR2, AKT 
and PLCγ were all dramatically phosphorylated in RKO 
vector control cells following 30 min stimulation with 25 
ng/ml VEGF165. NHERF1 overexpression significantly 
blocked VEGF165-induced VEGFR2 phosphorylation 
and inhibited the downstream AKT and PLCγ activation 
(Figure 5). Meanwhile the base levels of VEGFR2, AKT 
and PLCγ activation were not detectably different in cells 
transfected with NHERF1 plasmid or vector control.
NHERF1 inhibited the migration and invasion of 
RKO cells through VEGFR2 signaling pathway 
VEGF165-induced cell migration and invasion were 
investigated in RKO cells transfected with NHERF1 
plasmid and vector control, in order to explore whether the 
potential signaling transduction pathway was modulated 
by NHERF1. After pre-culture in serum-free medium 24 
h, cells were treated with 25 ng/ml VEGF165. NHERF1 
Table 1: Quantitative PCR analysis of NHERF1 expression in human colorectal tissues
Clinical data Grouping No. Median CI 95% p-value Mean ± SEM p-value
Tissue sample Normal 50 0.770 2.38 ± 0.56
Tumor 64 1.655 (−1.635,−0.121) 0.0083* 29 ± 15 0.093
Dukes stages A 6 16.15 16.3 ± 6.1
B 29 1.14 (−0.36,25.33) 0.11 26 ± 21 0.67
C 30 1.14 (−0.73,25.18) 0.10 30 ± 26 0.60
TNM stages 1 8 5.78 12.3 ± 5.2
2 27 1.25 (−1.28,20.85) 0.52 28 ± 23 0.51
3 24 1.12 (−1.51,21.01) 0.62 38 ± 32 0.45
Node Negative 35 1.37 24 ± 17
Positive 29 1.14 (−0.83,1.28) 0.98 31 ± 27 0.82
Survival status Disease free 19 0.89 2.94 ± 1.1
Recurrence 19 3.96 (−12.89,−0.25) 0.014* 14.9 ± 5.6 0.051
Metastasis 17 4.17 (−5.70,0.07) 0.079 8.7 ± 2.9 0.077
Death 10 1.0 (−3.0,1.1) 0.89 63 ± 61 0.35
Differentiation 1 2 0.715 0.715 ± 0.66
2 48 1.410 (−25.529,1.254) 0.39 18.5 ± 13 0.17
3 14 1.2 (−776.6,1.3) 0.47 62 ± 55 0.28
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significantly inhibited the migration (Figure 6A) and 
invasion (Figure 6B) rate of RKO cells induced by 
VEGF165 compared with vector control cells. On the 
contrary, VEGFR2 special inhibitor ZM-323881 removed 
the inhibitory effects of NHERF1 on the cell migration and 
invasion (Figure 6C, 6D). Similar results were also observed 
in HRT-18 cells (Supplementary Figure S1C, S1D). 
DISCUSSION
The VEGF/VEGFR signaling pathway is involved 
in cancer-related biological functions and is a therapeutic 
target in cancer [11]. Anti-VEGF treatment has proved 
efficacious and improves survival in CRC [12]. However, 
many patients progress after initial disease stabilization 
Figure 1: Prognosis value of VEGFR2 expression in colorectal cancer relied on the expression of NHERF1. The NHERF1 
protein was readily detected in both normal and cancerous epithelial cells of colorectal tissues, but not in surrounding stromal cells by IHC 
(A). High expression of VEGFR2 was associated with shorter overall survival of patients with colorectal cancer of low NHERF1 expression 
(B). No significant differences were observed in the OS curve analysis between patients with high and low VEGFR2 expression in the 
patients with colorectal cancer of high NHERF1 expression (C). 
Table 2: The association of the expression of NHERF1 and VEGFs/VEGFRs in human colorectal 
tissues
r vs NHERF1* p value*
VEGF A −0.10 0.36
VEGF B 0.01 0.87
VEGF C 0.005 0.96
VEGF D −0.07 0.42
VEGFR1 0.10 0.26
VEGFR2 0.25* 0.004*
VEGFR3 0.02 0.83
*Correlation coefficients by Spearman ranked correlation test, n = 114.
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due to acquired resistance to anti-VEGF/VEGFR drugs 
[14], suggesting that there is complicated regulation of 
VEGF/VEGFR pathway in vivo. Despite rapid progression 
in understanding the biology and the clinical significant 
of angiogenesis, there is very little information on the 
regulation of VEGF/VEGFR pathway specifically to 
tumor cells. 
In the present study, a high level expression of 
NHERF1 was found in colorectal cancer tissues and 
probably contributed to the malignant phenotypes of 
tumor recurrence and distant metastasis (Table 1). More 
interestingly, it was showed the expression of NHERF1 
was positively correlated with VEGFR2 expression 
(Table 2). High expression of VEGFR2 was associated 
with shorter overall survival of patients with colorectal 
cancer depending on the low NHERF1 expression (Figure 
1B, 1C). The overall survival rate analysis suggested 
NHERF1 could play an important role in the progression 
of colorectal cancer regulated by VEGFR2 signaling 
pathway. In the course of tumorogenesis, hypoxia becomes 
Figure 2: Exposure to hypoxia increased NHERF1 expression depending on the activation of VEGFR2 signaling 
pathway. Confluent cell monolayer of the human RKO cells were exposed to hypoxia (1% O2) for 15, 30, 60, 120 min and treated with 
(A) or without (B) ZM323881 (10 nM), VEGFR2 special inhibitor. NHERF1 and VEGFR2 expression was compared with non-treated 
monolayers by Western analysis. Histograms underneath each blot represent the trend of NHERF1 or VEGFR2 expression with (C, E) or 
without (D, F) ZM323881 (10 nM) normalized to GAPDH for three independent experiments. **p < 0.01
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Figure 3: Effects of NHERF1 expression on the migration and invasion of RKO cells. NHERF1 expression was detected 
in RKO cells transfected with flag-NHERF1 plasmid (A) and anti-NHERF1 siRNAs (B) The effects of NHERF1 overexpression and 
knockdown on cell migration (C, D) and invasion (E, F) were detected. The results represent the mean values ± SD of three independent 
experiments (C, D, E, F). *p < 0.05, **p < 0.01
Oncotarget7www.impactjournals.com/oncotarget
an essential feature of the neoplastic microenvironment, 
typically caused by inadequacy of the local vasculature to 
supply sufficient oxygen and nutrients to rapidly growing 
tumor cells [5]. HIF-1α is recognized as an important 
regulatory protein in the transcription of a variety of 
tumor related factors including VEGF-A and VEGFR2. 
VEGF-A in turn promotes the expression of HIF-1α. This 
is a positive feedback regulation pathway of tumor cells 
for adaptation to hypoxia microenvironment. Recently, 
it was also reported that the expression of NHERF1 was 
strongly correlated with higher expression of HIF-1α in 
colorectal cancers [31], suggesting association with the 
tumor hypoxia microenvironment. In the present study, the 
up-regulation of NHERF1 induced by hypoxia was found 
in RKO cells by strong correlation with the expression of 
VEGFR2 and HIF-1α (Figure 2A). The up-regulation of 
NHERF1 was removed by ZM-323881, VEGFR2 special 
inhibitor, suggesting that the up-regulation of NHERF1 
could be dependent on activation of VEGFR2 signaling 
pathway (Figure 2B). 
VEGF through the high affinity receptor tyrosine 
kinase VEGFR acts as a high inducer of the oncogenic 
cascades including Ras/MEK/ERK, PLC-γ-IP3, PI3K/
AKT to stimulate cell mitogenesis and cell migration [35]. 
In addition, the recent study showed that the expression 
of NHERF1 was increased by nuclear transcription 
factor NF-κB in the primary macrophages and vascular 
smooth muscle cells [36]. In colon cancer cells, NHERF1 
expression could be increased by the activation of NF-
κB signaling and/or the multiple downstream signaling 
pathway of HIF-1α/VEGF-A induced in the hypoxia 
microenvironment. This up-regulation of NHERF1 
Figure 4: NHERF1 interacted with VEGFR2. Glutathione S-transferases (GST)–NHERF1 beads were incubated with RKO cell 
lysates, and then the pull-down complexes were subjected to VEGFR2 immunoblotting (A) Coomassie blue-stained gel was used to 
visualize the same amount of input of fusion proteins. NHERF1 and VEGFR2 interacted in cells (B). RKO cell lysates were subjected 
to immunoprecipitation with the anti-VEGFR2 antibody or IgG as the negative control. The lysates were probed with the anti-NHERF1 
antibody or anti-VEGFR2 antibody to visualize the presence of NHERF1 and VEGFR2, respectively. NHERF1 co-localized with VEGFR2 
in native tissues (C). Normal and cancerous human colorectal tissues were fixed, permeabilized and probed with anti NHERF1 (shown in 
green) and anti-VEGFR2 (red). Nuclei were stained with Hoechst 33258. Co-localization was analyzed by confocal microscopy. The data 
shown in all panels of this figure are representative of three independent experiments. 
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was rapid for hypoxia (within 30 min) (Figure 2A, 2C) 
suggesting that NHERF1 could serve as a rapid response 
element to the tumor hypoxia microenvironment and 
might contribute to the regulation to the VEGF/VEGFR 
signaling pathway in driving metastatic progression. 
Clinical studies show an association between 
NHERF1 overexpression and malignant progression of 
colorectal cancers; however, there is very little information 
on the function of NHERF1 in in vitro studies specifically 
in colorectal cancer cells. In the present study, in vitro 
functional experiments showed that overexpression of 
NHERF1 reduced cell migration and invasion of RKO 
cells, and knockdown expression of NHERF1 enhanced 
the migratory and invasive ability of RKO cells, indicating 
a tumor suppressor role of NHERF1 in colon cancer cells 
specifically for metastasis (Figure 3). 
In addition to the VEGF receptors, Neuropilin-1 
(NP1) has been identified as a co-receptor for VEGF 
[37]. NP1 enhances the affinity of VEGF165 to VEGFR2 
and increases its phosphorylation, thereby enhancing 
downstream signaling [37, 38]. NHERF1, as a PDZ protein, 
might interact with NP1 through its PDZ-binding domain 
in the cytoplasm and further form a protein complex with 
VEGFR2, which could result in the regulation of the 
Figure 5: NHERF1 inhibited the phosphorylation activation of VEGFR2 and its downstream AKT and PLCγ activation 
induced by VEGF165. RKO cells transfected with Flag-NHERF1 plasmid were serum-free starved 24 h, and then stimulated with or 
without VEGF165 25 ng/ml for 30 min. Immunoblotting was performed using anti-p-VEGFR2, anti-VEGFR2, anti-pS473AKT, anti-AKT, 
anti-p-PLCγ, and anti-PLCγ antibodies (A). The signals were quantified by densitometry (B, C). The results represent the mean values ± 
SD of three independent experiments. *p < 0.05, **p < 0.01
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downstream signaling. This hypothesis was confirmed 
by the assays of GST-pull down, immunoprecipitation 
and immunofluorescence. Results showed NHERF1 
could interact with VEGFR2 in cells (Figure 4). The 
results of western blot (Figure 5) and in vitro functional 
experiments (Figure 6) showed NHERF1 reduced 
the migratory and invasive ability of RKO cells by 
inhibition of VEGF signaling pathway. These results 
suggested a negative feedback in colon cancer cells, in 
that the activation of VEGF signal pathway increased the 
expression of NHERF1 and NHERF1 in turn inhibited the 
phosphorylation activation of VEGFR2 and its downstream 
signals activation, resulting in reduction of the migration 
and invasion of colon cancer cells. Anti-VEGF/VEGFR 
drugs, targeted to suppress the tumor progression through 
anti-angiogenesis, in fact function both on tumor vascular 
endothelial cells and cancer cells. The up-regulation of 
NHERF1 exposed to hypoxia was also inhibited by the anti-
VEGF/VEGFR drugs in cancer cells. The negative feedback 
of NHERF1 to VEGF signaling pathway was disrupted, 
which could contribute to tumor progression, resulting in 
acquired resistance to anti-VEGF/VEGFR drugs. 
Figure 6: NHERF1 inhibited the migration and invasion of RKO cells through VEGFR2 signaling pathway. RKO cells 
transfected with Flag-NHERF1 plasmid were serum-free starved 24 h, and then cultured with or without VEGF165 25 ng/ml. NHERF1 
significantly inhibited cell migration (A) and invasion (B) induced by VEGF165. RKO cells transfected with NHERF1 plasmid were 
cultured in DMEM supplemented with 10% FBS with or without ZM-323881, VEGFR2 special inhibitor. ZM-323881 (10 nM) removed 
the inhibitory effects of NHERF1 on cell migration (C) and invasion (D) The results represent the mean values ± SD of three independent 
experiments (C, D). *p < 0.05, **p < 0.01
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Overall, in the present study, a high level expression of 
NHERF1 was found in colorectal cancer tissues and it was 
shown that expression of NHERF1 was positively correlated 
with VEGFR2 expression. NHERF1 expression induced by 
exposure to hypoxia could be dependent on the activation of 
VEGF signaling. NHERF1 in turn inhibited the activation 
of VEGFR2 signaling pathway which could be due to the 
interaction between NHERF1 and VEGFR2, resulting in 
the reduction of the migration and invasion of colon cancer 
cells. The present results suggest a dynamic interplay 
between NHERF1 and VEGFR2 signaling in colon cancer 
cells, which could explain the up-regulation of NHERF1 
in colorectal cancer and the contribution of NHERF1 
to the regulation of tumor cell responses to the hypoxia 
microenvironment. The administration of anti-VEGF/
VEGFR drugs could cause the downregulation of NHERF1 
expression in cancer cells, which could contribute to the 
progression of tumor and the acquired resistance to drugs. 
The expression of NHERF1 might be a potential predictive 
biomarker to identify patients that may benefit from anti-
VEGF/VEGFR therapies.
MATERIALS AND METHODS
Expression vectors and Small interfering RNAs
The GST-NHERF1 construct was kindly provided 
by Dr Jiale Dai, MD Anderson Cancer Center, Houston, 
TX. NHERF1 cDNA was cloned into pReceiver-M12 
vector to obtain the 3flag-tagged NHERF1 expression 
construct, according to the manufacturer’s instructions 
(New England BioLabs, Massachusetts, USA).  Small 
interfering RNA (siRNA) duplexes directed against 
NHERF1 (siNHERF1-1: 5-GUCGACCACCAGCAGG 
CGCACGGCGUUG-3; siNHERF1-2: 5-GCUAUGGCUU 
CAACCUGCATT-3) and the scrambled control RNA(5-
UCCAGACGGCGCAGUGGGCGACCGCUAC-3) were 
synthesized by Invitrogen (California, USA). 
Cell culture and transfection 
The human colon cancer cell line, RKO, was 
obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Cells were maintained in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% 
fetal calf serum, penicillin and streptomycin (Gibco BRC, 
Paisley, Scotland) and were cultured at 37°C in a 5% 
CO2, 95% humidified atmosphere. Cells were transiently 
transfected with Flag-NHERF1 plasmid and NHERF1-
siRNA respectively by using Lipo2000 (Invitrogen). 
Human colorectal specimens
Human colorectal cancer tissues (n = 64) and adjacent 
normal colorectal tissues (n = 50) were collected from patients 
after surgery. These tissues were collected immediately after 
surgery, and snap-frozen in liquid nitrogen, with the approval 
of the Local Ethical Committee (This study was conducted 
between 2002 and 2004 in UHW Cardiff-UK. Ethics were 
granted by the Cardiff and Vale NHS Trust, project ID: 05/
DMD/3562. Full patient consent was obtained). Background 
normal colorectal tissues (> 2 cm to the tumor) were 
removed from the same patients. The pathologist verified 
normal background and cancer specimens, and background 
samples were confirmed to be free from tumor deposits. The 
relevant information is provided in Table 1. Survival time 
was calculated from the date of surgery, and recurrence or 
metastasis was counted on the date of diagnosis thereof.
RNA preparation and real-time quantitative 
polymerase chain reaction (QPCR)
Total cellular RNA was isolated from the 
homogenized colorectal samples using the ABgene 
Total RNA Isolation Reagent and following the protocol 
provided (Advanced Biotechnologies Ltd., Epsom, 
Surrey, UK). cDNA was generated from 1 ug of each 
RNA sample and reverse transcribed using a transcription 
kit (Sigma, St. Louis, MO, USA). Quantitative analysis 
of NHERF1 mRNA expression in colorectal tissues 
was determined by QPCR using Amplifor™-based 
technologies, in which a 6-carboxy-fluorescine-tagged 
Uniprimer™ (Biosearch Technologies, Inc., Petaluma, 
CA, USA) was used as a probe together with a pair 
of target-specific primers and reverse primer with an 
additional Z-sequence (actgaacctgaccgtaca) (NHERF1 
QPCR primers – sense: AGGGAAACTGACGAGTTCTT; 
 antisense: ACTGAACCTGACCGTACATTCACGACTG 
TTCTCCTTCT). Real-time QPCR conditions were 
95°C for 15 min, followed by 60 cycles at 95°C for 20 
s, 55°C for 30 s and 72°C for 20 s. The quality of cDNA 
samples was verified using β-actin as a housekeeping 
gene (β-actin QPCR primers – sense: CATTAAGGAGAA 
GCTGTGCT; antisense: ACTGAACCTGACCGTACA 
GCTCGTAGCTCTTCTCCAG).
Wound-healing assay
The migratory properties of cells were assessed by 
wound-healing assay. Cells were seeded at a density of 1.5 
× 106 cells/well into a 6-well plate and allowed to reach 
confluence. The layer of cells was then scraped with a fine 
gauge needle to create a wound of approximately 1500 
µm. Images of the wound were recorded under a phase 
contrast microscope at different times (0, 6, 12, and 24 h). 
Wound closure/cell migration was evaluated with motion 
analysis and line morphometry software (Image J2x).
Cell invasion assay
Transwell chambers, equipped with a 6.5 mm 
diameter polycarbonate filter insert (pore size 8 µm) 
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(Becton Dickinson and Company, Oxford, UK), were pre-
coated with 50 µg/insert of Matrigel (BD Biosciences). 
Cells were seeded at a density of 2 × 104 cells/insert. 
3 days later, the cells that invade through the Matrigel were 
fixed, stained, and quantified as described before [39]. 
GST pull-down and Western blotting 
GST pull-down assays and Western blotting were 
performed as described previously [40]. The anti-NHERF1 
antibody was purchased from BD Biosciences; anti-
pS473AKT, anti-AKT, anti-pTyr783PLCγ, anti-PLCγ, 
HIF-1α and anti-Flag were from Cell Signaling Technology 
(Danvers, MA, USA); anti-Flk-1 (anti-VEGFR2) and anti-
pTyr1214 Flk-1 (anti-pVEGFR2) were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA); anti-GAPDH 
antibody were from ZSGB-Bio (Beijing, China). 
Immunoprecipitation
Cells were harvested and lysed in 1000 ml of ice-
cold lysis buffer (10 mM HEPES, 50 mM NaCl, 5 mM 
EDTA, 1 mM Benzamidine, 0.5% Triton X-100). The 
lysate was solubilized via end-over-end rotation at 4°C for 
40 min and clarified via centrifugation at 12,000 rpm for 
15 min.  A small fraction of the supernatant was taken at 
this point and incubated with SDS-PAGE sample buffer in 
order to examine expression of proteins in the whole cell 
extract. The remaining supernatant was divided equally 
into two tubes, and then incubated with 5 µg antibody and 
5 µg IgG (Cell Signaling Technology) respectively with 
end-over-end rotation at 4°C over night. After incubated 
with 30 ml of Protein A Sephasose (Ge Healthcare, 
Chicago, USA) for 3 h with end-over-end rotation at 4°C, 
the immunoprecipitated proteins were eluted from the 
beads with sodium dodecyl sulfate (SDS) sample loading 
buffer, resolved by SDS-PAGE and subjected to Western 
blot analysis with antibodies.
Immunofluorescence
Frozen sections of colorectal cancer tissues (n = 10) 
and background normal tissues (n = 10) were selected 
from the tissue bank and cut at a thickness of 6 µm 
using a cryostat. The sections were fixed with 4% 
paraformaldehyde in PBS at room temperature for 30min. 
Sections were incubated for 30 min in 5% BSA blocking 
solution and probed with monoclonal mouse anti-human 
NHERF1 primary antibody (1:100) (BD Biosciences) and 
polyclonal rabbit anti-human VEGFR2 primary antibody 
(1:100) (Santa-Cruz). This study employed controls that 
omitted the primary and secondary antibodies. Following 
extensive washings, sections were incubated with an Alexa 
Fluor® 488-conjugated anti-mouse IgG (Life Technologies, 
Massachusetts, USA) at 1:200 dilution and Alexa Fluor® 
594-conjugated anti-rabbit IgG (Life Technologies) at 
1:200 dilution in the dark for 1 h. After washing three times 
to remove the unbound secondary antibody, cell nuclei 
were stained with Hoechst 33258 (Sigma). The sections 
were finally mounted with FluorSave™ (Calbiochem-
Novabiochem Ltd., Nottingham, UK) and visualized with 
a confocal microscope (Leica Microsystems LAS AF-TCS 
SP5. Wetzlar, Germany).
Statistical analysis
SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA) 
was used for statistical analyses. The results were assessed 
using non-paired (two-sided) Student’s t-test and Mann-
Whitney U-test. The association of expression with the 
clinical and pathological features was analyzed using one-
way ANOVA. The Spearman rank test was used to analyze 
the correlation between NHERF1 expression and VEGFR2 
expression. Overall survival rates were calculated using 
the Kaplan-Meier method. The log-rank test was utilized 
to compare the survival rates between groups with varying 
VEGFR2 expression levels.  A p-value < 0.05 was defined 
as statistically significant. 
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